Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

Fig. 4

The effects of selegiline in cerebellum mask the reduction of 18F-THK5351 standardized uptake value ratio. Standardized uptake value ratio (SUVR) map overlaid on a structural MRI scan showing the baseline and 1 h post-selegiline SUVR from 50 to 70 min after 18F-THK5351 injection in the eight patients. AD Alzheimer’s disease, MCI mild cognitive impairment, PSP progressive supranuclear palsy, y.o years old

Back to article page